Avastin (bevacizumab) / Roche - LARVOL DELTA

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. (PubMed, Nat Commun) - P2 | "QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • ALK

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "In patients with advanced hepatocellular carcinoma with macrovascular invasion after systemic therapy, time to treatment failure was longer in those who had liver resection than in those who received maintenance therapy."

Clinical • Journal • P3 data • Hepatocellular Cancer • Hepatology • Liver Failure • Oncology • Renal Disease • Solid Tumor

Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial (ESMO 2026) - No abstract available

Late-breaking abstract • Metastases • P3 data • Colorectal Cancer • Oncology • Solid Tumor

Three-Year Follow-Up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Non-Curable Stage IV Colon Cancer (JCOG1107). (PubMed, Dis Colon Rectum) - P3 | "Laparoscopic surgery is non-inferior to open surgery for non-curable stage IV colon cancer and should be considered an acceptable surgical option. See Video Abstract."

Journal • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Palliative care • Solid Tumor • BRAF • MSI

Cell-Resolution Explainable Atezolizumab+Bevacizumab Response Signature Prediction (ABRS-P) in Hepatocellular Carcinoma (HCC) using Cell Graphs (ESMO-AI 2026) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor

Gastrointestinal and Renal Adverse Events following Kidney SBRT for Renal Cell Carcinoma: Impact of Recent Systemic Therapy Use (ASTRO 2026) - "Recent systemic therapy was defined as RCC-directed agent within 6 months pre- or 12 months post-SBRT, classified as multitarget tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or other (everolimus, belzutifan, bevacizumab)...TKIs included cabozantinib (n=11), axitinib (n=9), lenvatinib (n=8), and tivozanib (n=1)... BP rates were higher among kidney SBRT patients treated with recent combination TKI+ICI therapy. Given the retrospective design and limited sample size, results should be interpreted cautiously."

Adverse events • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience. (ASCO 2022) - P3 | "Molecular clusters of patients have been identified and correlated with outcomes in the phase 3 IMmotion151 (IM151) trial of atezolizumab + bevacizumab (IO+VEGF) vs. sunitinib (Sun) (Motzer, Cancer Cell 2020 &JAMA Oncol 2021). Avelumab+axitinib (AA) is an approved IO+VEGF combination in mRCC... We were able to largely validate the molecular clusters classification and some of the associations with survival outcomes from IM151 in the JR101 clinical trial cohort. Biomarkers of specific VEGF+IO combinations in mRCC should be prospectively validated in randomized trials. >Cluster 7 separately was excluded as it contains 1 patient per treatment arm."

Clinical • IO biomarker • Genito-urinary Cancer • Immune Modulation • Inflammation • Oncology • Renal Cell Carcinoma • Solid Tumor

Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma. (PubMed, JCO Precis Oncol) - "The 15G score was independently prognostic in metastatic ccRCC among patients receiving different systemic therapy regimens."

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (clinicaltrials.gov) - P2 | N=38 | Active, not recruiting | Sponsor: The Netherlands Cancer Institute | Trial completion date: Aug 2025 ➔ Dec 2028 | Trial primary completion date: Aug 2025 ➔ Dec 2028

Trial completion date • Trial primary completion date • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Rectal Cancer • Solid Tumor

KOSMOS-II: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II (clinicaltrials.gov) - P=N/A | N=1000 | Active, not recruiting | Sponsor: Seoul National University Bundang Hospital | Recruiting ➔ Active, not recruiting | Trial primary completion date: Sep 2026 ➔ Mar 2027

Enrollment closed • Trial primary completion date • Tumor mutational burden • Oncology • Solid Tumor

Prognostic role of the Child-Turcotte-Pugh classification and ALBI grade in patients without cirrhosis and hepatocellular carcinoma. (PubMed, JHEP Rep) - "CTP classification and ALBI grade are associated with prognosis in patients without cirrhosis and HCC, and their prognostic power is comparable to that in patients with cirrhosis and HCC."

Biomarker • Journal • Cardiovascular • Fibrosis • Hepatocellular Cancer • Hypertension • Immunology • Liver Cancer • Oncology • Portal Hypertension • Solid Tumor

Right-To-Left Stage Migration in Advanced Hepatocellular Carcinoma: A Case Report of a Successful Multimodal Approach. (PubMed, Case Rep Oncol) - "The optimal integration of systemic immunotherapy and locoregional treatment in advanced HCC represents a novel field. No clear evidence has yet been provided regarding the role of systemic therapy as induction in BCLC stage C. Our case report suggests that atezolizumab plus bevacizumab and multidisciplinary approach could improve survival outcomes and treatment definition in selected, advanced HCC patients: it also highlights the importance of interdisciplinary interactions and collaboration in order to ensure the correct therapeutic sequencing."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CTLA4

A Case of Nephrotic Syndrome Developing Early After Initiation of Fruquintinib Therapy (PubMed, Yakugaku Zasshi) - "loxoprofen and magnesium oxide were discontinued and furosemide was initiated...The Naranjo score were 7 for fruquintinib, 6 for loxoprofen and bevacizumab, and 5 for trifluridine/tipiracil hydrochloride, suggesting probable adverse drug reaction...Although renal biopsy was not performed, thrombocytopenia and elevated lactate dehydrogenase suggested thrombotic microangiopathy. Earlier monitoring could have enabled faster detection and prevention of severe symptoms."

Journal • Cardiovascular • Colorectal Cancer • Dermatology • Fatigue • Glomerulonephritis • Hematological Disorders • Hypertension • Nephrology • Oncology • Pulmonary Disease • Renal Disease • Solid Tumor • Thrombocytopenia

Comparative Effectiveness and Safety of FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer: A GRADE-assessed Systematic Review and Meta-analysis. (PubMed, J Gastrointest Cancer) - "FOLFOXIRI-cetuximab did not improve PFS, OS, or response rates in patients with mCRC compared with the bevacizumab combination; however, it was associated with significantly higher rates of hypomagnesemia and acneiform rash."

Clinical • HEOR • Journal • Retrospective data • Review • Alopecia • Colorectal Cancer • Dental Disorders • Hematological Disorders • Immunology • Oncology • Solid Tumor • Stomatitis

Anti-VEGF–Induced Necrotic Angiodermatitis (Martorell-like Ulcer) in a Patient Treated with Atezolizumab–Bevacizumab (EADV 2026) - "Accurate diagnosis relies on clinicopathologic correlation and exclusion of mimickers. Early recognition is essential, as management differs significantly and requires multidisciplinary coordination."

Clinical • Cardiovascular • Dermatitis • Dermatology • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Peripheral Arterial Disease • Pyoderma Gangrenosum • Solid Tumor • Thrombosis • Vasculitis

Intralesional Biologics in Dermatology: A Systematic Review (EADV 2026) - "Rituximab was the most frequently reported intralesional biologic, while other agents included adalimumab, dupilumab, brentuximab vedotin, spesolimab, secukinumab, guselkumab, bevacizumab, nivolumab, talimogene laherparepvec, and interleukin-2-based therapies. However, the currently available evidence is limited by marked heterogeneity and the predominance of low-level evidence, especially case reports. Further prospective and controlled studies are needed to better define efficacy, safety, optimal dosing strategies, and the most appropriate indications for intralesional biologic therapy in dermatology."

Review • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Extranodal Marginal Zone Lymphoma • Fibrosis • Hematological Malignancies • Immunology • Kaposi Sarcoma • Lichen Planus • Lymphoma • Marginal Zone Lymphoma • Melanoma • Mucosal Melanoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Pemphigus Vulgaris • Prurigo Nodularis • Psoriasis • Sarcoidosis • Sarcoma • Solid Tumor • IL2

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) (clinicaltrials.gov) - P3 | N=690 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases (ESMO-GI 2025) - P1 | "This is the first presentation of a fully enrolled expanded cohort of pts with MSS mCRC NLM from the phase 1b trial. As of Mar 13, 2025, 123 pts with NLM were enrolled / treated with BOT every 6 wks (62 pts – 1 mg/kg, 61 pts – 2 mg/kg) plus BAL every 2 wks (3 mg/kg). Median age, 56 yrs (range 25–82); median prior lines, 3 (range 1–10); 58% ≥1 metastatic site, 16% treated liver metastases; 16% prior I-O, 30% prior regorafenib, trifluridine/tipiracil ± bevacizumab or fruquitinib; and 67% RAS mutant. BOT / BAL, a novel I-O only combination, demonstrates unprecedented clinical benefit with deep, durable responses, and for the first time, meaningful treatment free survival in refractory MSS mCRC NLM, with a manageable safety profile."

Clinical • IO biomarker • Metastases • Colorectal Cancer • Oncology • Solid Tumor

NCI-2022-09458: FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • POLE

A phase 1 trial of folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) in microsatellite stable metastatic colorectal cancer. (ASCO-GI 2025) - P1/2 | "FOLFOX-3B with BOT at 75 mg IV Q6 weeks x 2 in combination with BAL 240 mg Q2 weeks is well-tolerated and is associated with promising clinical activity with 5/6 PR and prolonged PFS. The study was amended to explore additional DL that explore higher doses of BOT (150 mg) or longer duration of BOT 75mg (4 doses)."

IO biomarker • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • TMB

First-in-human study of an implantable microdevice for personalized drug testing in colorectal liver metastases. (ASCO-GI 2026) - "Reservoirs will be loaded with cytotoxic and immunomodulatory agents formulated in polyethylene glycol (PEG), including 5-fluorouracil (5-FU), FOLFOXFIRI (5-FU, oxaliplatin, leucovorin, irinotecan), bevacizumab, Fc–enhanced multifunctional anti–CTLA–4 antibody (botensilimab, AGEN1181), anti–PD–1 antibody (balstilimab), and anti–CD137 antibody (AGEN2373)...Doxorubicin autofluorescence will allow orientation and confirm local drug diffusion... This is the first–in–human study of IMDs in CRLM, establishing a novel in vivo platform for rapid, patient-specific therapeutic profiling. If successful, IMDs could redefine therapeutic development in CRLM by enabling real-time, patient-specific drug testing to guide precision treatment."

First-in-human • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. (ASCO-GI 2026) - "The IMbrave150 phase 3 study demonstrated that combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab (atezo/bev) extends survival compared to sorafenib in first-line treatment of advanced and intermediate stage HCC failing/unsuited for TACE which has led to its approval in this setting. The results of the first IA provide important insights into the efficacy of atezo/bev vs. TACE in intermediate stage HCC and suggest a superiority of systemic therapy compared to TACE in regard to TTFS. Based on these findings, the trial is progressing to the second IA at 66% information time (169 events)."

Clinical • P3 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "In this exploratory analysis of the KEYNOTE-826 randomized clinical trial, the 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy (with or without bevacizumab) as a first-line standard-of-care option for recurrent and metastatic cervical cancer. ClinicalTrials.gov Identifier: NCT03635567."

Clinical • Journal • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1

A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study. (PubMed, Br J Cancer) - P=N/A | "Sequential treatment with REGO and FTD/TPI plus BEV therapy yielded comparable survival, suggesting that treatment selection may depend on safety profiles of each drug."

Journal • Observational data • Cardiovascular • Colorectal Cancer • Dermatology • Hematological Disorders • Hypertension • Neutropenia • Oncology • Renal Disease • Solid Tumor

Impact of Bevacizumab on Mucosal Healing After Dental Extraction (ESMO 2026) - No abstract available

Oncology